X4 Pharmaceuticals Inc (XFOR)

X4 Pharmaceuticals Stock Analysis & Ratings

XFOR Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.86 - $6.68
Previous Close$1.04
Average Volume (3M)362.10K
Market CapN/A
Enterprise ValueN/A
P/E Ratio-0.3
Next EarningsAug 03, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score8



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was X4 Pharmaceuticals’s price range in the past 12 months?
X4 Pharmaceuticals lowest stock price was $0.86 and its highest was $6.68 in the past 12 months.
    What is X4 Pharmaceuticals’s market cap?
    Currently, no data Available
    What is X4 Pharmaceuticals’s price target?
    The average price target for X4 Pharmaceuticals is $9.25. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $13.00 ,the lowest forecast is $7.00. The average price target represents 789.42% Increase from the current price of $1.04.
      What do analysts say about X4 Pharmaceuticals?
      X4 Pharmaceuticals’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
        When is X4 Pharmaceuticals’s upcoming earnings report date?
        X4 Pharmaceuticals’s upcoming earnings report date is Aug 03, 2022 which is in 29 days.
          How were X4 Pharmaceuticals’s earnings last quarter?
          X4 Pharmaceuticals released its earnings results on May 12, 2022. The company reported -$0.72 earnings per share for the quarter, missing the consensus estimate of -$0.601 by -$0.119.
            Is X4 Pharmaceuticals overvalued?
            According to Wall Street analysts X4 Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does X4 Pharmaceuticals pay dividends?
              X4 Pharmaceuticals does not currently pay dividends.
              What is X4 Pharmaceuticals’s EPS estimate?
              X4 Pharmaceuticals’s EPS estimate is -$0.63.
                How many shares outstanding does X4 Pharmaceuticals have?
                X4 Pharmaceuticals has 30,823,572 shares outstanding.
                  What happened to X4 Pharmaceuticals’s price movement after its last earnings report?
                  X4 Pharmaceuticals reported an EPS of -$0.72 in its last earnings report, missing expectations of -$0.601. Following the earnings report the stock price went down -0.952%.
                    Which hedge fund is a major shareholder of X4 Pharmaceuticals?
                    Among the largest hedge funds holding X4 Pharmaceuticals’s share is New Leaf Venture Partners, L.L.C.. It holds X4 Pharmaceuticals’s shares valued at 586K.


                      X4 Pharmaceuticals Stock Analysis

                      Smart Score
                      Price Target
                      ▲(789.42% Upside)
                      Strong Buy
                      The X4 Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      X4 Pharmaceuticals Inc

                      X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan and is headquartered in Cambridge, MA.

                      Similar Stocks
                      Price & Change
                      Ovid Therapeutics
                      Crinetics Pharmaceuticals
                      Sutro Biopharma
                      Orchard Therapeutics
                      Mersana Therapeutics

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis